Short-Term Relative Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-19 Vaccinations in South Korea
Gwak, E.; Choe, S.-A.; Bolormaa, E.; Choe, Y. J.; Wang, C.; Fix, J.; Vadivale, M.; Rousculp, M. D.
Show abstract
To estimate the relative, short-term effectiveness of NVX-CoV2373 versus BNT162b2 (Pfizer- BioNTech) in preventing SARS-CoV-2 infection and severe COVID-19 disease during the Omicron variant dominance in South Korea. Retrospective cohort-study among [≥]12-year-olds using the K-COV-N database, which links COVID-19 vaccine registry data with health insurance claims data. The Cox proportional-hazards model and inverse probability of treatment weighting were employed to calculate adjusted hazard ratios (aHRs). Among homologous primary-series NVX-CoV2373 versus BNT162b2 recipients, the aHR was 0.86 (95% CI: 0.82-0.91) for all laboratory-confirmed and 0.80 (95% CI: 0.48-1.33) for severe infections. Among homologous 1st-booster recipients, it was 0.74 (95% CI: 0.61-0.90) for all laboratory-confirmed and 0.48 (95% CI: 0.12-1.92) for severe infections. At 30-days post-immunization, we observed homologous, NVX-CoV2373 primary-series and 1st-booster offered added protection against SARS-CoV-2 infection versus BNT162b2; while there was numerically lower risk of severe disease among NVX-CoV2373-vaccinated, no statistically significant differences were observed.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea 97%
- A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines 96%
- Antibody Response after Second-dose of ChAdOx1-nCOV (Covishield™ ® ) and BBV-152 (Covaxin™ ® ) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study 96%
Similar papers in this journal
- Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study 95%
- Effectiveness of Covid-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): A systematic review with meta-analysis and meta-regression 95%
- Safety and immunogenicity of the BBIBP-CorV vaccine in adolescents aged 12-17 years in Thai population, prospective cohort study 95%
Similar papers in this journal
- Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine 96%
- Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults 95%
- Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study 94%
Similar papers in this journal
- Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China 95%
- Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study 94%
- Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study 94%
Similar papers in this journal
- Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong 94%
- Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial 94%
- A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.